HomeElixir Medical

Elixir Medical

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

Data shows the DynamX Coronary Bioadaptor System is the first coronary artery implant that adapts to vessel physiology.

Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-approved DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System

The company reports:  Excellent Six-Month Safety and Efficacy Results for Next-Generation Thin-strut DESolve® Cx Novolimus Eluting Bioresorbable Coronary Scaffold System also presented Elixir Medical Corporation, announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial...

Elixir Medical to Release Five-year DESolve Nx Trial Data, Showcase Next-Generation Coronary and SFA Bioresorbable Scaffold Systems at EuroPCR 2017

Long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve™ Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the...